Core Viewpoint - The strategic cooperation between Yunzhisheng Intelligent Technology Co., Ltd. and Fangchenggang City aims to advance the "AI + healthcare" systematic construction, responding to the national strategy for developing the Guangxi Fangchenggang International Medical Open Experimental Zone [2][4]. Group 1: Strategic Cooperation Details - The cooperation framework includes a specific execution agreement signed between Yunzhisheng and the Fangchenggang Health Commission, with the commission acting as the implementation unit [2]. - The partnership will leverage the core advantages of both parties in public healthcare services and AI technology, adhering to principles of co-construction, shared benefits, and collaborative development [2]. - Key areas of focus for future collaboration include digital transformation of healthcare, quality improvement of grassroots information systems, AI infrastructure development, innovative management models for the "three medicines," multilingual medical service platforms, and industrial collaboration within the international medical open experimental zone [2]. Group 2: Implementation and Goals - Fangchenggang's Deputy Mayor Xu Wei emphasized the importance of this cooperation for advancing smart healthcare in the city, outlining three specific requirements: system integration and empowerment upgrades, establishing interconnectivity within the healthcare system, and a phased approach focusing on key areas to create demonstrable results [3]. - Yunzhisheng's Chairman Liang Jiaen highlighted the company's commitment to integrating AI technology with industry needs, aiming to develop expert-level models and solutions for the healthcare sector [4]. - The strategic partnership marks a significant step towards implementing the "AI + healthcare" model in Fangchenggang, with plans for future expansion across Guangxi, nationwide, and into the ASEAN region [4].

Core Viewpoint - The company, Yunzhisheng (09678), has made significant progress in the commercialization of its foundational large model and intelligent agent platform, collaborating with well-known domestic enterprises to implement projects valued at nearly RMB 200 million, with delivery planned by the end of 2025 [1] Group 1 - The company has established deep cooperation with domestic partners to advance its foundational large model and intelligent agent projects [1] - The implementation of these projects is based on the company's proprietary computing scheduling platform, Shanhai large model, and Shouya Agent intelligent platform [1] - This progress signifies a solid step forward in the commercialization process of the company's foundational large model and intelligent agent platform [1] Group 2 - The advancements further validate the company's technological leadership in foundational large models and intelligent agent platforms [1] - The company plans to deepen its research and commercialization efforts in the smart living sector, leveraging its strong advantages [1]

Core Insights - The company, Yunzhisheng (09678.HK), has made significant progress in the commercialization of its foundational large model and intelligent agent platform [1] - The company has partnered with well-known domestic enterprises to implement projects valued at nearly RMB 200 million, utilizing its proprietary computing scheduling platform, Shanhai large model, and Shouya Agent intelligent platform [1] - The delivery of these projects is planned to be completed by the end of 2025, indicating a solid step forward in the commercialization process [1] Company Developments - The advancements signify the recognition of the company's technological leadership in foundational large models and intelligent agent platforms [1] - The company aims to further deepen its research and commercialization efforts in the smart living sector, leveraging its strong advantages [1]

Core Insights - The company, Yunzhisheng (09678), has made significant progress in the commercialization of its foundational large model and intelligent agent platform [1] - The company has partnered with well-known domestic enterprises to implement projects valued at nearly RMB 200 million, with delivery planned by the end of 2025 [1] - This advancement indicates the company's leading position in the technology of foundational large models and intelligent agent platforms [1] Summary by Categories Commercialization Progress - The company has achieved substantial progress in the commercialization of its foundational large model and intelligent agent platform [1] - The implementation of projects worth approximately RMB 200 million is underway, showcasing the company's ability to attract significant partnerships [1] Technological Leadership - The advancements signify further recognition of the company's technological leadership in foundational large models and intelligent agent platforms [1] - The company plans to deepen its research and commercialization efforts in the smart living sector, leveraging its strong advantages [1]

UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 本公告乃由雲知聲智能科技股份有限公司（「本公司」）自願作出，旨在知會本公司股東 及潛在投資者有關本公司的最新業務發展情況。 本公司董事會（「董事會」）欣然宣佈，本公司基礎大模型和智能體平台商業化取得實質 性進展，近日與國內知名企業等合作夥伴深入合作，將基於自有知識產權的算力調度平 台、山海大模型以及獸牙Agent智能體平台，實現價值近人民幣2億元的基礎大模型和智 能體項目實施部署，計劃將於2025年底前完成交付。 該進展意味著本公司在基礎大模型和智能體平台商業化落地進程中邁出了堅實的一步， 同時也標誌著公司基礎大模型和智能體平台技術的領先性得到進一步認可。本公司將 在具備深厚優勢的智慧生活領域進一步深耕大模型和智能體的研發及商業化落地。 承董事會 ...

二零二五年八月修訂 | 目 錄 | | --- | | 第一章 總則 | 1 | | --- | --- | | 第二章 經營宗旨及範圍 | 3 | | 第三章 股份 | 4 | | 第四章 股份增減和回購 | 8 | | 第五章 股東名冊 | 10 | | 第六章 股東的權利和義務 | 12 | | 第七章 股東會 | 16 | | 第八章 董事會 | 33 | | 第九章 董事會秘書 | 45 | | 第十章 總經理及其他高級管理人員 | 46 | | 第十一章 財務會計制度與利潤分配和審計 | 48 | | 第十二章 合併、分立、增資、減資、解散和清算 | 53 | | 第十三章 修改章程 | 59 | | 第十四章 通知 | 60 | | 第十五章 附則 | 61 | 第一章 總則 雲知聲智能科技股份有限公司 公司章程 公 司 系 由 北 京 雲 知 聲 信 息 技 術 有 限 公 司（以 下 簡 稱「雲知聲有 限」）整 體 變 更 發 起 設 立 的 股 份 有 限 公 司，在 北 京 市 工 商 行 政 管 理局海淀分局註冊登記，取得營業執照，統一社會信用代碼為 91110108599663854 ...

及 修 訂《 公 司 章 程 》 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 2025 年第二次臨時股東大會投票結果 取消監事會 茲提述雲知聲智能科技股份有限公司（「本公司」）日期均為2025年9月30日的2025年第二 次臨時股東大會（「臨時股東大會」）通告（「臨時股東大會通告」）及通函（「該通函」）。除文 義另有所指外，本公告所用詞彙與臨時股東大會通告及該通函所界定者具有相同涵義。 臨時股東大會已於2025年10月17日（星期五）上午10時正於雲知聲智能科技股份有限公司 二層會議室（中國北京市海淀區建材城中路27號金隅智造工場N6號樓）以現場會議形式 舉行。臨時股東大會由董事會召開並由本公司董事長、執行董事兼首席技術官梁家恩博 士主持。全部董事均出席臨時股東大會。 於臨時股東大會日期， ...

Core Insights - The company has successfully won a bid for multiple AI capability platform projects with Beijing Friendship Hospital, marking significant progress in the smart healthcare sector [1][2] - The project utilizes the company's self-developed medical large model and core technologies for multi-modal data recognition and governance, establishing an intelligent service platform for the hospital [1] - The implementation of this platform has led to substantial improvements in data value extraction and diagnostic efficiency, with specific examples including an 80% increase in medical record entry efficiency and a 15% reduction in consultation time [1] Industry Developments - This initiative aligns with national policies promoting AI empowerment in healthcare, transitioning smart healthcare from single-scenario intelligence to comprehensive digital solutions across the entire diagnosis and treatment process [2] - The company has reinforced its leading position in the healthcare intelligence competition, leveraging its advanced medical capabilities demonstrated in authoritative evaluations like MedBench and its experience with over 30% of top-tier hospitals nationwide [2]

Core Insights - The company, Yunzhisheng (09678), has successfully won a bid for multiple AI capability platform projects with Beijing Friendship Hospital, marking a significant advancement in its smart healthcare technology and commercial application [1] Group 1: Project Details - The project utilizes the company's self-developed medical large model, multimodal data recognition and governance, and text reasoning technologies to create an intelligent service platform that hospitals can operate independently [1] - The platform integrates the hospital's knowledge base to form a specialized medical large model, breaking through traditional medical information construction models [1] Group 2: Operational Efficiency - The company has achieved unified management of multiple models and intelligent integration with business systems, significantly enhancing data value extraction and diagnostic efficiency in various scenarios such as wound image recognition, infection risk assessment, intelligent medical record generation, and follow-up management [1] - For instance, the outpatient medical record generation system at Beijing Friendship Hospital improved record entry efficiency by 80% and reduced consultation time by 15%, leading to a substantial increase in patient satisfaction [1] Group 3: Strategic Alignment - This project aligns with national policies promoting AI empowerment in healthcare, facilitating the transition from single-scenario intelligence to comprehensive digital solutions across the entire diagnostic and treatment process [1] - The company consolidates its leading position in healthcare intelligence competition, leveraging its advanced medical capabilities demonstrated in authoritative evaluations like MedBench and its experience covering over 30% of top-tier hospitals nationwide [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責任。 最新業務進展 本公告乃由雲知聲智能科技股份有限公司（「本公司」）自願作出，旨在知會本公司股東 及潛在投資者有關本公司的最新業務發展情況。 UNISOUND AI TECHNOLOGY CO., LTD. 雲知聲智能科技股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：9678） 自願性公告 於本公告日期，本公司董事會包括：(i)執行董事梁家恩博士、黃偉博士、康恒博士、李霄寒先生、劉升平先生及 李鵬先生；(ii)非執行董事鄺子平先生、李志超先生、汪存富先生及李昂先生；及(iii)獨立非執行董事胡建軍先生、 樊健先生、金慧華女士、張坤博士及陳華先生。 本公司董事會（「董事會」）欣然宣佈，本公司成功中標首都醫科大學北京友誼醫院（「北 京友誼醫院」）AI能力平台等多個智能體（Agent）項目，實現與北京友誼醫院在目前合作 基礎上服務關係的進一步深化，也標誌著本公司在智慧醫療領域的技術落地和商業 ...